semaglutide and bone loss density Tirzepatide, a dual GLP-1 and GIP receptor agonist, promotes bone in obese mice via gut microbial-related metabolites Research is raising questions about

Lancet 12-13-1980;2(8207):1309-1310

In a 48-week study involving 338 non-diabetic adults with obesity: To put this in perspective: A patient weighing 250 pounds could potentially lose 60 pounds in less than a year on Retatrutide

The combination of the medication and preexisting gastroparesis symptoms could exacerbate nausea and vomiting. I dont recommend people who have a history of an eating disorder take GLP-1 drugs unless they absolutely need treatment, says Sue Decotiis, MD, triple board-certified physician in New York City

Gene expression levels were quantified by qPCR using QuantiFast SYBR Green PCR Kit (Qiagen, Chatsworth, CA, USA) and reactions were performed on a Viia TM 7 real time PCR system (Life Technologies, Gaithersburg, MD, USA)

Fukutomi, T., Takagi, K., Mizushima, T., Ohuchi, N